-

11:22:21 PM

OCUP Stock News

OCUP - Ocuphire Pharma Inc

05/19/22 7:00 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial for the Large Unmet Need of Treating Night Vision Disturbances (NVD) in Subjects Experiencing Glare,

RHEA-AI

neutral

05/13/22 8:00 AM

Nasdaq : OCUP

earningslow float

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in First Quarter NDA Filing on Track for Late 2022 for Potential 2023 Approval of Nyxol as Only Dilation Reversal Drop Data Expected in 2H22 from

RHEA-AI

neutral

05/11/22 8:00 AM

Nasdaq : OCUP

conferencesclinical triallow float

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by

RHEA-AI

neutral

04/28/22 7:00 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials MIRA-4 Results Support Potential Broader Label for Nyxol in RM to Include Pediatrics NDA Filing for

RHEA-AI

positive

04/26/22 9:00 AM

Nasdaq : OCUP

low float

Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a

RHEA-AI

positive

04/19/22 8:00 AM

Nasdaq : OCUP

managementconferenceslow float

Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic

RHEA-AI

positive

04/06/22 8:00 AM

Nasdaq : OCUP

conferenceslow float

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch,

RHEA-AI

neutral

03/29/22 7:00 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Meets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects (p<0.0001) MIRA-3 Confirms Prior MIRA-2 Phase 3 Registration Trial Showing Substantial Benefit in Accelerating Reversal of Mydriasis (RM) NDA Filing for

RHEA-AI

neutral

03/24/22 8:00 AM

Nasdaq : OCUP

earningslow float

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update

Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022: – Nyxol ® MIRA-3 Phase 3 Results Expected End of 1Q 2022 – MIRA-4 Pediatric, and LYNX-1 Phase 3 Results Expected to follow in 2Q 2022 – ZETA-1 Phase 2 Diabetic

RHEA-AI

positive

03/16/22 7:30 AM

Nasdaq : OCUP

clinical triallow float

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy

Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022 APX3330 as an Oral Therapy Has the Potential to Treat Over 7 Million Diabetic Retinopathy Patients With Limited Treatment Options Rapid Enrollment for

RHEA-AI

neutral

1 2 3 4 5 6 Next

OCUP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ocuphire.com
CeoDouglas Swirsky
Security nameOcuphire Pharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees5
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address15245 Shady Grove Rd Ste 455
StateMaryland
CityRockville
Zip20850-7203
CountryUS
Phone12402685300

About Ocuphire Pharma Inc

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® Eye Drops, is a once-dailypreservative-free eye drop formulation of phentolamine mesylate, a non-selectivealpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire's second product candidate, APX3330, is a twice- a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets.